At Idea Therapeutics, we are a biotech powerhouse committed to developing, co-creating and manufacturing groundbreaking, ready-to-use Advanced Therapy Medicinal Products (ATMPs) in the fields of regenerative and autoimmune medicine.
We aspire to be a leading biotech powerhouse in ATMP development, pushing boundaries in autoimmune, inflammatory and regenerative diseases, enlightening the future of health to improve patient’s lives.
Enlightening ATMPs with end-to-end execution, GMP manufacturing and an open-innovation ecosystem that accelerates patient impact.
Idea Therapeutics was founded in 2020 by a team of healthcare executives from FARMALIDER, a leading Spanish pharmaceutical company with a strong track record in developing Rx, OTC and innovative products for the global B2B market.
Together, we aim to develop disruptive cell therapies using allogeneic cells for complex and medical conditions with limited therapeutic options. The founders’ goal is to offer treatments that are scalable and accesible to millions of patients worldwide.
Marisa Berenguer has been CEO of Farmalider since 2015, where she has led the company’s international expansion, diversification into new therapeutic areas, and the strengthening of its innovation pipeline. With a solid background in corporate finance, business strategy, and licensing, she has driven global strategic partnerships and sustainable growth models in the healthcare sector. In 2023, she co-founded Idea Therapeutics, a biotech start-up focused on advanced therapies, where she currently serves as CEO. She also leads several biotech spin-offs, is a member of the Board of Directors of Farmalider and other biotech companies, and actively invests in life sciences ventures, supporting the development of disruptive solutions in biomedicine. Her leadership combines scientific vision, financial expertise, and strategic focus, positioning her as a reference in bridging biotech innovation with scalable international business growth.
José Ángel holds a PhD in Physical and Chemical Sciences from UAM (2010). He was head of the Technology and Knowledge Transfer Unit at the Madrid Institute of Materials Science (CSIC). Between 2021 and 2023, he served as a Project Control Specialist for R&D at CDTI. From 2016 to 2020, he was Director of R&D Operations at FARMALIDER. Previously, from 2012 to 2016, he was Project Manager and Head of the Advanced Materials and Surfaces Laboratory at Tecnalia BRTE.
PhD in Cellular Biology and Genetics from UAM (2009). For the past 8 years, she has been the Technical Manager of the GMP cleanroom dedicated to the manufacture of advanced therapy medicinal products (ATMPs) at Hospital Clínico San Carlos (Madrid). She has been involved in the design and manufacturing process of tumor-infiltrating lymphocytes (TILs) isolated from solid tumors in compliance with GMP standards, as well as in the design and manufacturing process of CD133+ stem cells isolated from patients with liver metastases of colorectal origin undergoing major liver resection. From 2009 to 2015, she was a postdoctoral researcher in regenerative medicine, studying the role of mesenchymal stem cells in maintaining tissue homeostasis and exploring various signaling pathways during the differentiation of OA-MSC and healthy donors.
PhD in Biological Sciences in the field of Medical-Surgical Sciences (2025) and a MSc in Translational Medicine Research both from University Complutense of Madrid. She conducted her doctoral research at the Hospital Clínico San Carlos in Madrid where she specialized in cell therapy in the context of androgenetic alopecia. She possesses a strong background in experimental animal research, in particular, design and execution of preclinical in vivo studies, animal model development, data analysis and research project management. Regarding clinical studies, she has participated in a wide range of phase II, III and IV clinical trials in the field of dermatology and internal medicine.
He is a renowned dermatologist with international prestige. Head of the Dermatology Department at the San Carlos Clinical Hospital. First Director of the Institute of Skin Diseases and Surgery at the same hospital. Founder and Director of Clínica Imema, where he currently leads the Trichology and Hair Transplant Unit, which received the «Innovative SME» seal from the Ministry of Science and Innovation for its new treatment protocols for androgenetic alopecia. Doctor of Medicine and Surgery from the Complutense University of Madrid, with an Extraordinary Award, and Associate Professor of Dermatology at the Faculty of Medicine of the Complutense University. He is co-author of more than 300 publications. He has directed over 50 courses, symposia, and congresses, both in Spain and abroad, including the International Master’s Degree in Trichology and Hair Transplant at the Complutense University of Madrid. He has supervised numerous doctoral theses and Bachelor’s theses, and has received various awards for his scientific and research work. Among them: five consecutive years ranked within the 100 best doctors in Spain according to Forbes, within the 30 leading doctors in Aesthetics according to Forbes Women, and in both editions of Forbes Books’ Best Doctors. He is also listed among the best and most internationally prestigious Spanish doctors according to ABC, Telva, and Elle. Winner of the Actualidad Económica Award and the Madrigallego de Oro in the field of health. Chosen by Top Doctors as one of the 50 best doctors in the country. Additionally, he is a prominent advisor on health and beauty for Spain’s leading media outlets. A reference dermatologist and trichologist for the Efe Salud Agency. An international leader in hair transplantation, he is the only European member of the World Medical Council of Restoration Robotics, the leading company in medical robotics for hair restoration. He is responsible for more than 70 clinical research trials, including those for minoxidil and finasteride (both oral and topical), pharmacological treatments currently approved for androgenetic alopecia. He is the Principal Investigator and Scientific Director of the first global project in stem cell therapy for the treatment of male and female androgenetic alopecia.
Let’s enlighten your business together.
